Krystal Biotech (KRYS) EBT Margin (2023 - 2026)

Krystal Biotech has disclosed EBT Margin across 4 years of filings, most recently posting 52.8% for Q1 2026.

• EBT Margin for Q1 2026 came in at 52.8%, up 337.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 49.69% (up 829.0% YoY), and the FY2025 annual result was 48.69%, up 1587.0% from the prior year.
• EBT Margin came in at 52.8% for Q1 2026 at Krystal Biotech, up from 47.74% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 943.75% in Q3 2023 to a low of 2.06% in Q1 2024.
• The 4-year median for EBT Margin is 48.72% (2025), against an average of 120.96%.
• Across the five-year window, EBT Margin sank 90824 bps in 2024 and jumped 4738 bps in 2025, its largest moves.
• Krystal Biotech's EBT Margin stood at 25.29% in 2023, then jumped by 111 bps to 53.35% in 2024, then fell by 11 bps to 47.74% in 2025, then increased by 11 bps to 52.8% in 2026.
• The last three EBT Margin figures came in at 52.8% (Q1 2026), 47.74% (Q4 2025), and 49.05% (Q3 2025), per Business Quant data.